loading...| Preferred Name |
Pan-LOX Inhibitor PXS-5505 |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C179584 |
| CAS_Registry |
2409963-83-1 |
| code |
C179584 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 |
| Contributing_Source |
CTRP GDC FDA |
| DEFINITION |
An orally available, small-molecule, irreversible inhibitor of all lysyl oxidases (LOX) family members, with potential antifibrotic activity. Upon oral administration, pan-LOX inhibitor PXS-5505 targets, binds to and inhibits the activity of all enzymes in the LOX family. This prevents the post-translational oxidative deamination of lysine residues on target proteins, including collagen and elastin, and reduces the formation of deaminated lysine (allysine), the formation of inter- and intramolecular cross-linkages and may prevent remodeling of the extracellular matrix (ECM), thereby reducing fibrotic tissue formation in certain chronic fibrotic diseases. LOX is often upregulated in fibrotic tissue and plays a key role in fibrosis. |
| Display_Name |
Pan-LOX Inhibitor PXS-5505 |
| FDA_UNII_Code |
DO94E28WYW |
| FULL_SYN |
Pan-LOX Inhibitor PXS-5505 PXS 5505 PXS-5505 PXS5505 LOX Inhibitor PXS-5505 |
| Has_Target | |
| label |
Pan-LOX Inhibitor PXS-5505 |
| NCI_Drug_Dictionary_ID |
804787 |
| NCI_META_CUI |
CL1662187 |
| Preferred_Name |
Pan-LOX Inhibitor PXS-5505 |
| prefixIRI |
Thesaurus:C179584 |
| prefLabel |
Pan-LOX Inhibitor PXS-5505 |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||